Overview

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Phase:
PHASE3
Details
Lead Sponsor:
Sun Pharmaceutical Industries Limited
Treatments:
tildrakizumab